[{"id":"c2c2adc0-fff1-4c4f-86b0-e88c3d04d52a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06435455","created_at":"2024-05-31T20:35:26.953Z","updated_at":"2024-07-02T16:34:59.697Z","phase":"Phase 1/2","brief_title":"GH21 Combined With D-1553 With Advanced Solid Tumors","source_id_and_acronym":"NCT06435455","lead_sponsor":"Suzhou Genhouse Bio Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anfangning (garsorasib) • HBI-2376"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-05-31"},{"id":"9c82a02e-5ff8-41e1-bc14-085d8f246f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT05163028","created_at":"2021-12-20T16:53:57.143Z","updated_at":"2024-07-02T16:35:37.281Z","phase":"Phase 1","brief_title":"A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations","source_id_and_acronym":"NCT05163028","lead_sponsor":"HUYABIO International, LLC.","biomarkers":" EGFR • KRAS","pipe":" | ","alterations":" KRAS mutation • EGFR mutation","tags":["EGFR • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HBI-2376"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/13/2021","start_date":" 12/13/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-09-13"}]